Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05302583 | RECRUITING | Cancer Distress

Aromatherapy Inhaler Use for HSCT Distress
Sponsor:

Stanford University

Brief Summary:

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Condition or disease

Cancer Distress

Cancer Coping

Hematopoetic Stem Cell Transplant

Aromatherapy

Intervention/treatment

Aromatherapy Inhaler

Phase

NA

Detailed Description:

Phase 1: Transplant Day +1, +2, or +3. Phase 2: Washout Day: Standard of care (SOC) pharmacological intervention only. Phase 3: Transplant Day +3, +4, or +5). Study Completion: Transplant Day +4, +5, or +6. \*Study activities will occur on a single day for each phase. However, a three-day window for Phases 1 and 3 will allow consideration of patients' ability to participate in the immediate post-transplant period.

Study Type : INTERVENTIONAL
Estimated Enrollment : 50 participants
Masking : NONE
Primary Purpose : SUPPORTIVE_CARE
Official Title : Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Actual Study Start Date : 2025-06-16
Estimated Primary Completion Date : 2026-03
Estimated Study Completion Date : 2026-03

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Autologous and Allogeneic patients admitted to E1 for planned HSCT
  • * Patients with hematologic malignancies requiring HSCT
  • * No allergies to lavender or peppermint essential oils
  • * Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
  • * Adult patient over 18 years of age
  • * Able to speak, read, and comprehend English
  • * Willing and capable of providing informed consent
Exclusion Criteria
  • * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
  • * Patients receiving a transplant for a germ cell tumor diagnosis
  • * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
  • * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
  • * History of scleroderma
  • * History of atrial fibrillation
  • * Known history of G6PD deficiency
  • * Allergic to lavender or peppermint essential oils
  • * Pediatric patient 18 years of age or less
  • * Unable to speak, read, and comprehend English
  • * Unwilling or incapable of providing informed consent
Aromatherapy Inhaler Use for HSCT Distress

Location Details

NCT05302583

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Stanford University

Stanford, California, United States, 94305